Table 2.
Summary of treatment-emergent adverse events occurring at a frequency of at Least one percent in either study drug group (safety population Hispanic subjects)
| PREFERRED ADVERSE EVENT | CLINDAMYCIN-BP 3.75% | VEHICLE (N=72) | P-VALUE |
|---|---|---|---|
| Nasopharyngitis | 2 (3.3) | 1 (1.4) | 0.593 |
| Pharyngitis | 0 (0.0) | 1 (1.4) | 1.000 |
| Headache | 1 (1.6) | 1 (1.4) | 1.000 |
| Sinus headache | 1 (1.6) | 1 (1.4) | 1.000 |
| Facial Pain* | 0 (0.0) | 1 (1.4) | 1.000 |
| Swelling face* | 0 (0.0) | 1 (1.4) | 1.000 |
| Ligament sprain | 0 (0.0) | 1 (1.4) | 1.000 |
| Upper respiratory tract infection | 0 (0.0) | 1 (1.4) | 1.000 |
Note: Treatment-emergent adverse events are those with an onset after the first application of study medication. Those marked with an asterisk (*) were considered to be treatment-related